PUBLISHER: The Business Research Company | PRODUCT CODE: 1942595
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942595
Congenital heart defect devices are specialized medical instruments and implants designed to address and manage heart abnormalities present from birth. These devices are used to diagnose, treat, and support the heart's function in individuals with congenital heart defects, aiming to restore normal blood flow and enhance cardiac performance.
The primary types of congenital heart defect devices include catheters, pacemakers (single-chamber, dual-chamber, biventricular, and leadless), implantable cardioverter defibrillators, biventricular devices, and implanted cardiac loop recorders. Catheters are slender, flexible tubes inserted into the body for various functions such as diagnostic, therapeutic, or monitoring purposes. These devices are used for different types of congenital defects, including ventricular septal defect, atrioventricular septal defect, tricuspid atresia, truncus arteriosus, and others. They are employed by hospitals, specialty clinics, academic and research institutions, and other healthcare settings.
Tariffs are impacting the congenital heart defect devices market by increasing costs for imported medical-grade materials, electronic components, and precision-engineered parts used in pacemakers, catheters, and implantable cardiac devices. These cost pressures have particularly affected advanced implantable and transcatheter device segments, with north america and europe experiencing higher exposure due to complex global supply chains. Increased tariffs have raised procurement costs for hospitals and specialty clinics. However, tariffs have also encouraged localized manufacturing, supplier diversification, and regional production expansion, strengthening long-term supply chain resilience.
The congenital heart defect devices market research report is one of a series of new reports from The Business Research Company that provides congenital heart defect devices market statistics, including congenital heart defect devices industry global market size, regional shares, competitors with a congenital heart defect devices market share, detailed congenital heart defect devices market segments, market trends and opportunities, and any further data you may need to thrive in the congenital heart defect devices industry. This congenital heart defect devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The congenital heart defect devices market size has grown strongly in recent years. It will grow from $3.11 billion in 2025 to $3.34 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to rising incidence of congenital heart defects, advancements in pediatric cardiac surgery, increasing survival rates of congenital heart patients, expansion of specialized cardiac care centers, growing awareness of early congenital defect diagnosis.
The congenital heart defect devices market size is expected to see strong growth in the next few years. It will grow to $4.45 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing focus on early diagnosis and intervention, rising demand for minimally invasive pediatric cardiac treatments, expanding access to advanced cardiac care in emerging markets, growing population of adults with congenital heart disease, continuous innovation in implantable cardiac devices. Major trends in the forecast period include rising adoption of minimally invasive congenital heart procedures, increasing use of transcatheter and implantable cardiac devices, growing focus on early-life and pediatric cardiac interventions, expansion of device-based therapies for complex heart defects, increasing demand for long-term cardiac monitoring and support devices.
The growth of the congenital heart defect device market is anticipated to be driven by the rising number of minimally invasive procedures. These procedures involve performing surgeries through small incisions or natural body openings, using specialized tools and techniques to minimize trauma and improve recovery. Factors contributing to the increase in minimally invasive procedures include technological advancements, patient preference for less invasive treatments, enhanced surgical techniques, and the advantages of reduced recovery times and complications. Congenital heart defect devices play a crucial role in these procedures by enabling the diagnosis, treatment, and management of heart abnormalities through smaller incisions or catheter-based approaches. For example, in June 2024, according to the American Society of Plastic Surgeons, a US-based organization, plastic surgeries in 2023 increased by 5%, while minimally invasive procedures grew by 7% compared to the previous year. This rise in minimally invasive procedures is consequently boosting the congenital heart defect device market.
Major players in the congenital heart defect (CHD) devices market are increasingly forming strategic partnerships to develop innovative solutions. These partnerships help companies in the CHD devices sector by combining resources and expertise, enhancing research and development efforts, expanding market reach, and accelerating the commercialization process. Such collaborations foster innovation and contribute to industry growth. For example, in May 2024, SMT (Sahajanand Medical Technologies Pvt Ltd), an India-based manufacturing company, entered into a partnership with HeartX, an India-based MedTech firm, to improve patient care in the cardiovascular sector. Through this collaboration, Sahajanand Medical Technologies (SMT) strengthens its presence in the CHD market by incorporating HeartX's cutting-edge solutions, such as the JOVE VB Stent. This alliance enables SMT to provide advanced CHD devices that improve treatment effectiveness, simplify procedures, and enhance patient outcomes.
In June 2023, Translumina Therapeutics LLP, an India-based cardiovascular device manufacturer, acquired Wellinq Group Company for an undisclosed sum. This acquisition aims to broaden Translumina's cardiovascular and endovascular solutions portfolio and strengthen its market presence in the Netherlands by integrating Blue Medical Devices' innovative technologies and expertise. Wellinq Group Company, based in the Netherlands, specializes in developing and manufacturing products for treating congenital heart defects.
Major companies operating in the congenital heart defect devices market are Johnson & Johnson, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, W L Gore & Associates Inc, Lepu Medical Technology Beijing Co Ltd, MicroPort Scientific Corporation, Berlin Heart GmbH, Syncardia Systems LLC, Occlutech Holding AG, Sahajanand Medical Technologies Pvt Ltd, Xeltis AG, Procyrion Inc, Heartstitch Inc, Cardia Inc, OSYPKA Medical GmbH, On-X Life Technologies Inc, Ventracor Limited, HemoFlow Technologies, NuPulseCV Inc
North America was the largest region in the congenital heart defect devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congenital heart defect devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the congenital heart defect devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The congenital heart defect devices market consists of sales of septal occluders, heart valves, patent ductus arteriosus (PDA) devices, and bioprosthetic devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Congenital Heart Defect Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses congenital heart defect devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for congenital heart defect devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The congenital heart defect devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.